The University of Michigan Rogel Cancer Center researchers received one of the Prostate Cancer Foundation’s four inaugural Class of 2022 TACTICAL (Therapy ACceleration To Intercept Cancer Lethality) Award. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer [...]

One of the most fascinating aspects of a career in cancer research is that one never knows when or where the next great discovery will occur. This was true of a recent breakthrough discovery made by the Dr. Russell Ryan laboratory at the University of Michigan Medical School. They were shocked to find that active regulatory elements in B-ALL contained not only typical protein binding sequences but also simple repeats of the sequence “GGAA”, usually considered a form of “junk DNA” with no regulatory function [...]

Members of the University of Michigan Department of Pathology and Michigan Center for Translational Pathology, in collaboration with the Clinical Proteomic Tumor Analysis Consortium, recently published a large study on clear cell renal cell carcinomas (ccRCCs), which represent about 75% of the RCC cases and account for the most RCC-associated deaths. This study set out to create a comprehensive profile of ccRCC, combining histologic and molecular profiles. By analyzing both the microscopic cell structures and the genetic makeup of the cells, these researchers discovered significant intratumoral heterogeneity in 90% of ccRCCs. This indicates that ccRCCs originate from multiple tumor cell lines, called tumor subclones, that may become metastatic and could independently influence response to therapies. Through this study, the team was able to molecularly stratify aggressive histopathic subtypes, which may lead to more effective treatment strategies for patients and improved survival.

A research team from the Michigan Center for Translational Pathology undertook a study to illustrate how careful assessment of cytologic and biomarker features may provide physicians with information on Metastatic Prostatic Cancer (MCP) patients’ prognosis and the best therapies to consider [...]

The Celina Kleer lab at the University of Michigan Department of Pathology and Rogel Cancer Center has found a new mechanism that fuels metastasis in triple negative breast cancers. In their new study they show that EZH2, a master regulator of cell type identity, known to function through methylation of histones, has a new, unexpected function in aggressive breast cancers [...]

Effective July 1, 2022, Dr. Sriram Venneti, Professor of Pathology, was appointed as Scientific Research Director and Dr. Carl Koschmann, Assistant Professor of Pediatrics, was appointed as Clinical Research Director for the Chad Carr Pediatric Brain Tumor Center (CC-PBTC).

We recognize Dr. Jolanta Grembecka on being named the inaugural Richard and Susan Rogel Professor of Cancer Therapeutics. An induction ceremony will be held later this year. Please join us in congratulating her on this honor!

A landmark study into quantitative image analysis in ER, PgR, and HER2 in invasive breast carcinoma was recently published in the American Journal of Clinical Pathology. Dr. Mustafa Yousif, Assistant Professor of Breast Pathology and Informatics, and colleagues conducted a retrospective study of 1,367 invasive breast carcinomas of all histopathology subtypes, for which ER, PgR, and HER2 were analyzed by manual scoring [...]

What is skin cancer and how can you prevent it?

The role of artificial intelligence (AI) in healthcare continues to expand. In a recent issue of BMC Cancer, Dr. Vipulkumar Dadhania (first author) and colleagues published a result of their study Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. The expert team from the Michigan Center for Translational Pathology developed a deep-learning-based model to predict ERG genomic rearrangements in prostatic adenocarcinomas using only H&E-stained digital slides [...]

Please join us in congratulating Dr. Abhijit Parolia on being selected for the 2022 Harold Weintraub Graduate Student Award. The award, established by the Fred Hutchinson Cancer Research Center, is given yearly and recognizes outstanding achievement during graduate studies in the biological sciences [...]

The Royal Swedish Academy of Sciences, which also awards the Nobel Prizes, announced today that Arul Chinnaiyan, MD, PhD, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine and Director of the Michigan Center for Translational Pathology, has been selected as [...]

Research from INHERET was just published in the Journal of the National Comprehensive Cancer Network (JNCCN). Learn more about this study, which analyzes the implementation of InheRET's online tool that provides information about family history as it relates to cancer risks [...]

 A multi-institutional study led by Drs. Alex Taylor, Noah Brown and Rohit Mehra from the Department of Pathology was just published in European Urology's Open Science. Learn more about the resarch, which focuses on how TERT promoter mutations were characterized in urinary tract lesions, which may be considered as precursors to neoplasia at this site [...]

A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.

Research pertaining to Merkel cell carcinoma (MCC) and cutaneous neuroendocrine carcinomas was just published in the latest edition of Modern Pathology. Led by the team of Drs. Paul Harms, May Chan, Aaron Udager, Rajiv Patel, and more [...]

Research from experts in the Department of Pathology was published in Europe PMC's Histopathology. The team comprised of Drs. Jiaqi Shi, Laura Lamps and Erika Hissong examined the impact of adenomatoid tumors within the gastrointestinal tract [...]

Dr. Xiao-Ming (Mindy) Wang and colleagues from the Michigan Center for Translational Pathology and Department of Pathology published a groundbreaking finding from an inter-institutional study regarding TRIM63 in Modern Pathology  [...]

Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?

Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach. Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia [...]

Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments – and wildly different outcomes for patients as a result. By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers from the University of Michigan Rogel Cancer Center have identified the cells [...]

A research effort by Drs. Jolanta Grembecka and Tomasz Cierpicki was just published in Nature Communications. Learn more about the protein made by the ASH1L gene, which plays a key role in the development of acute leukemia, along with other diseases [...]

Research from the Department's Lombard Lab was just published in the Journal of Clinical Investigation. The study, which focuses on how the deacylase SIRT5 compound supports melanoma viability by influencing chromatin dynamics, was led by Dr. Lombard [...]

Stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models.

Congratulations to Arul Chinnaiyan, MD, PhD, who was announced as the Science of Oncology Award and Lecture recipient by the American Society of Clinical Oncology (ASCO). As part of this award, Chinnaiyan will present a 30-minute lecture entitled “Exploring Precision Oncology: from Gene Fusions to Related Genetic Drivers“ at the ASCO Annual Meeting, to be held virtually on June 4-8, 2021 [...]

A new publication from the Department of Pathology, led by Dr. Kathleen Cho, was just published in the American Association for Cancer Research's flagship journal. highlights how altering the microbiome within a mouse model of oviductal high-grade serious carcinoma can inhibit tumorigeneis [...]

MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.

A new study, led by U-M graduate in molecular and cellular pathology Dr. Andi Cani, was just published in European Urology Oncology. The publication focuses on the development of a whole-urine, multiplexed, next-generation RNA-sequencing assay that is used for the early detection of aggressive forms of prostate cancer [...]

Dr. Mehra discusses his career path and how he arrived at Michigan Medicine in our latest Careers in Pathology video.

A collaboration between the Department of Pathology and the Department of Dermatology examined biomarkers of outcomes in 346 cases of Merkel cell carcinoma (MCC), an aggressive type of skin cancer. The study was published in the recent edition of Clinical Cancer Research [...]

A new publication, generated by Department of Pathology faculty members Drs. Aaron Udager and Scott Tomlins was successfully published in European Urology. The research highlights a longitudinal cohort study centered around the serial molecular profiling of low-grade prostate cancer in order to better assess tumor upgrading [...]

A new study by the University of Michigan's Rogel Cancer Center analyzed patients with cancer and the factors that cause the cancer to spread to the liver, leading to worse outcomes. 

Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus. wo proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, MD, PhD. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers [...]

A new study led by Drs. Jolanta Grembecka and Tomasz Cierpicki of the Department of Pathology was just published in Blood's American Society of Hematology. The research focuses on combinatorial treatment with menin and FLT3 and how inhibitors induce complete remission in acute myeloid leukemia (AML) with activating FLT3 mutations [...]

Congratulations to Dr. Thomas Giordano and the entire Cancer Genome Atlas Project team for winning the American Association of Cancer Research's 2020 Team Science Award [...]

Congratulations to Dr. Celina Kleer who was awarded the American Society for Investigative Pathology (ASIP)'s 2020 Outstanding Investigator Award. Dr. Kleer receives the award for her demonstrated excellence in research in experimental pathology [...]

10:00 am EST

Join us for a virtual event featuring the Department of Pathology's Dr. Celina Kleer, who will host a discussion related to her experiences in understanding breast cancer and her journey as a physician-scientist.

Register Now

Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family, whose malfunction is associated with several types of cancer.

Dr. Aaron Udager recently appeared on Michigan Medicine's 3P's of Cancer: Prevention, Preparedness, Progress podcast

The research was just published in Modern Pathology and highlights the importance of next-generation sequencing within oncogenic roles for P53 and JAK/STAT signaling in microcystic adnexal carcinomas.

The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.

The research was just published in Histopathology and features prominent contributions from our faculty.

Researchers have uncovered the gene signature for ChRCC.

A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.

U-M researchers are shedding new light with exciting implications for research and health.

Chan Chung, PhD, received two grants in funding from the ChadTough Foundation and Defeat DIPG foundation ($150,000) and the Robert Connor Dawes CERN Pediatric Fellowship ($100,000). [...]

Andi Cani, PhD, successfully defended his thesis entitled “Precision Medicine Approaches to Hormone-Driven Cancer” on December 5, 2019. [...]

The National Cancer Institute’s (NCI) Predoctoral to Postdoctoral Fellow Transition (F99/K00) Award supports outstanding PhD and other Research Doctoral candidates who complete their dissertation research training (F99 phase) and transition in a timely manner to mentored, cancer-focused postdoctoral career development research positions (K00 phase). [...]

The American Association for Cancer Research announced that Celina Kleer, MD, the Harold A. Oberman Collegiate Professor of Pathology and Director of the Breast Pathology Program, will be the recipient of the 2019 Outstanding Investigator in Breast Cancer Research, supported by the Breast Cancer Research Foundation.

Bryan Betz, PhD, was inspired by his late wife, Sharon, to pursue a career in clinical diagnostics.

Speaking directly with a pathologist could help patients better understand their diagnosis and feel empowered, a survey of patient sentiment finds.

Surinder Kumar, Ph.D., has received The Pablove Foundation Childhood Cancer Research Grant for his proposal entitled “The sirtuin SIRT5 as a novel therapeutic target for Ewing’s Sarcoma” [...]

Every year in the United States, nearly 3 million men hear the words, “You have prostate cancer.” That is 1 in 9 men each year.  The word “cancer” triggers an immediate response in most people…fear, worry about family, denial, and often an increased awareness of one’s mortality. [...]

Researchers characterize 3 ways in which the gene FOXA1 mutates to trigger prostate cancer.